GlassScriptPhysician profile
Mara Tijerina
NPI 1801501838
$1,634.58
in general payments reported to CMS, 2019-2025
24 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.58 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $361.72 | 2025 | Tecvayli, Darzalex, Talvey |
| Pharmaessentia USA Corporation | $196.22 | 2025 | Besremi |
| Pfizer INC. | $163.57 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $91.74 | 2025 | Imfinzi |
| Array Biopharma INC | $75.70 | 2025 | Mektovi, Braftovi, Tukysa |
| Merck Sharp & Dohme LLC | $73.31 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Iovance Biotherapeutics, INC. | $71.49 | 2025 | Amtagvi |
| Vertex Pharmaceuticals Incorporated | $59.00 | 2025 | |
| Stemline Therapeutics INC. | $56.31 | 2025 | Orserdu |
| Genentech USA, INC. | $53.09 | 2025 | Venclexta, Polivy |
| Daiichi Sankyo INC. | $52.31 | 2025 | Datroway, Enhertu |
| Abbvie INC. | $51.74 | 2025 | |
| Incyte Corporation | $48.94 | 2025 | Jakafi, Monjuvi |
| Tersera Therapeutics LLC | $36.69 | 2025 | Zoladex, Xermelo |
| Sobi, INC | $34.66 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $31.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.46 | 2025 | Fruzaqla |
| Alexion Pharmaceuticals, INC. | $25.44 | 2025 | Ultomiris |
| Fennec Pharmaceuticals, INC. | $25.42 | 2025 | Fyarro |
| Genzyme Corporation | $24.10 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.89 | 2025 | |
| Kyowa Kirin, INC. | $18.00 | 2025 | |
| Adc Therapeutics America, INC. | $16.92 | 2025 | |
| Genmab U.S., INC. | $16.39 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Tijerina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.